methylprednisolone has been researched along with Parkinson Disease, Secondary in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Che, NN; Chen, SY; Li, X; Ma, JJ; Yang, HQ | 1 |
| Ikeda, K; Iwamoto, K; Iwasaki, Y; Mizumura, S; Tachiki, K; Yanagihashi, M | 1 |
| Fujita, K; Nishimura, A; Sawada, T; Takada, H; Takeuchi, Y | 1 |
3 other study(ies) available for methylprednisolone and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Autoimmune-mediated secondary-parkinsonism presented with micrographia and cognitive impairment.
Topics: Adult; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Antiparkinson Agents; Autoantibodies; Benserazide; Cognitive Dysfunction; Drug Combinations; Fever of Unknown Origin; Handwriting; Humans; Immunosuppressive Agents; Immunotherapy; Levodopa; Male; Methylprednisolone; Neuropsychological Tests; Parkinson Disease, Secondary; Tremor | 2021 |
Combined treatment of methylprednisolone pulse and memantine hydrochloride prompts recovery from neurological dysfunction and cerebral hypoperfusion in carbon monoxide poisoning: a case report.
Topics: Antiparkinson Agents; Carbon Monoxide Poisoning; Cerebrovascular Circulation; Cerebrovascular Disorders; Drug Therapy, Combination; Glucocorticoids; Humans; Hyperbaric Oxygenation; Male; Memantine; Methylprednisolone; Middle Aged; Neurotoxicity Syndromes; Parkinson Disease, Secondary; Perfusion Imaging; Pulse Therapy, Drug; Recovery of Function; Time Factors; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2014 |
Serial MRI in infantile bilateral striatal necrosis.
Topics: Basal Ganglia Diseases; Betamethasone; Caudate Nucleus; Child, Preschool; Corpus Striatum; Diagnosis, Differential; Dominance, Cerebral; Female; Humans; Magnetic Resonance Imaging; Methylprednisolone; Necrosis; Neurologic Examination; Neuromuscular Diseases; Parkinson Disease, Secondary; Putamen | 1994 |